Stifel Nicolaus Reiterates Buy Rating for Spark Therapeutics, Inc. (NASDAQ:ONCE)
Stifel Nicolaus reissued their buy rating on shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) in a report released on Thursday morning. They currently have a $92.00 target price on the biotechnology company’s stock, up from their prior target price of $77.00.
ONCE has been the subject of a number of other reports. Jefferies Group LLC began coverage on Spark Therapeutics in a report on Monday, July 10th. They issued a buy rating and a $85.00 price target for the company. Cantor Fitzgerald set a $94.00 price target on Spark Therapeutics and gave the stock a buy rating in a report on Monday, July 17th. ValuEngine downgraded Spark Therapeutics from a hold rating to a sell rating in a research report on Saturday, May 20th. BidaskClub upgraded Spark Therapeutics from a sell rating to a hold rating in a research report on Thursday, June 22nd. Finally, Zacks Investment Research upgraded Spark Therapeutics from a strong sell rating to a hold rating in a research report on Wednesday, July 19th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $82.27.
Shares of Spark Therapeutics (NASDAQ:ONCE) traded up 0.14% during trading on Thursday, reaching $76.96. The company’s stock had a trading volume of 2,519,357 shares. The stock’s market cap is $2.38 billion. The stock has a 50-day moving average of $63.15 and a 200-day moving average of $58.70. Spark Therapeutics has a 52-week low of $35.07 and a 52-week high of $78.08.
Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.75) by $0.14. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The company had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.33 million. During the same period in the previous year, the business earned ($1.04) earnings per share. Spark Therapeutics’s revenue was up 14.7% on a year-over-year basis. Analysts predict that Spark Therapeutics will post ($6.80) earnings per share for the current fiscal year.
WARNING: “Stifel Nicolaus Reiterates Buy Rating for Spark Therapeutics, Inc. (NASDAQ:ONCE)” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/06/stifel-nicolaus-reiterates-buy-rating-for-spark-therapeutics-inc-nasdaqonce.html.
In other news, insider Katherine A. High sold 10,000 shares of Spark Therapeutics stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $60.00, for a total value of $600,000.00. Following the transaction, the insider now owns 220,000 shares in the company, valued at $13,200,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, General Counsel Barge Joseph La sold 5,000 shares of Spark Therapeutics stock in a transaction dated Wednesday, June 7th. The stock was sold at an average price of $55.00, for a total value of $275,000.00. Following the completion of the transaction, the general counsel now owns 9,567 shares in the company, valued at approximately $526,185. The disclosure for this sale can be found here. In the last quarter, insiders sold 314,310 shares of company stock worth $21,866,838. Company insiders own 7.30% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ONCE. FMR LLC increased its position in Spark Therapeutics by 0.9% in the first quarter. FMR LLC now owns 4,656,655 shares of the biotechnology company’s stock valued at $248,386,000 after buying an additional 40,698 shares in the last quarter. BlackRock Inc. increased its position in Spark Therapeutics by 11,332.0% in the first quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock valued at $98,158,000 after buying an additional 1,824,117 shares in the last quarter. Vanguard Group Inc. increased its position in Spark Therapeutics by 5.2% in the first quarter. Vanguard Group Inc. now owns 1,827,660 shares of the biotechnology company’s stock valued at $97,487,000 after buying an additional 90,686 shares in the last quarter. JPMorgan Chase & Co. increased its position in Spark Therapeutics by 7.8% in the first quarter. JPMorgan Chase & Co. now owns 1,549,093 shares of the biotechnology company’s stock valued at $82,628,000 after buying an additional 112,596 shares in the last quarter. Finally, Wellington Management Group LLP increased its position in Spark Therapeutics by 119.5% in the first quarter. Wellington Management Group LLP now owns 808,782 shares of the biotechnology company’s stock valued at $43,140,000 after buying an additional 440,287 shares in the last quarter. Hedge funds and other institutional investors own 88.96% of the company’s stock.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.